Business Context and Reporting Period
This Form 6-K filing by Akari Therapeutics Plc, dated March 4, 2022, discloses the execution of an Executive Employment Agreement with Ms. Rachelle Jacques. The agreement appoints her as President and Chief Executive Officer, effective no later than May 28, 2022. The filing also notes that outgoing CEO Clive Richardson will resign as a director on the Start Date but will remain with the company to support the transition.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and employment terms.
- Annual Base Salary: $600,000
- Target Annual Cash Bonus: 50% of base salary ($300,000)
- Target Long-Term Incentive (2023+): 100% of base salary ($600,000)
- One-Time Signing Bonus: $650,000 (subject to clawback provisions)
- Initial Restricted Stock Units (RSUs): $262,000 value
- Annual RSU Awards (Years 1 & 2): $446,000 value each
- Stock Option Grant: 4% of issued share capital on the Start Date
Material Changes
The primary material change is the leadership transition. Ms. Jacques replaces Clive Richardson as CEO. The filing details significant compensation commitments, including a substantial one-time cash bonus and equity grants representing a significant portion of the company's share capital. The agreement includes specific provisions for acceleration of equity vesting in the event of a change of control or involuntary termination without cause.
Guidance, Outlook, and Risks
The filing does not contain financial guidance or operational outlook. However, it outlines specific risks and contingencies related to the executive agreement:
- Clawback Risk: The $650,000 signing bonus is subject to partial repayment if Ms. Jacques resigns without good reason or is terminated for cause within the first two years.
- Termination Costs: In the event of termination without cause or resignation for good reason, the company is obligated to pay the sum of the annual base salary and target bonus, plus pro-rated bonuses and COBRA premium reimbursements for up to 12 months.
- Change of Control: Termination within 18 months of a change of control triggers enhanced severance, including the greater of the current or previous year's salary and bonus targets.
Investor Verification Checklist
- Verify the exact "Start Date" to confirm the vesting schedule for the 4% stock option grant and the timing of the $650,000 signing bonus.
- Confirm the current share capital to calculate the precise number of shares included in the 4% stock option grant.
- Review the performance goals established by the Board for the annual cash bonus to assess achievability.
- Monitor the transition plan to ensure Clive Richardson's departure does not disrupt ongoing business development or clinical trials.
- Check the company's cash position to ensure it can fund the immediate $650,000 cash bonus and future annual compensation obligations.